EUVIMEDScopri EUVIMED
Multizentrische Studie

A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19

Mohammed Abul Kashem, Gabriel Loor iD, Amir Emtiazjoo, Matthew Hartwig, Dirk Van Raemdonck iD, Hannah Calvelli iD, Andres Leon Pena, Marcelo Salan-Gomez iD, Huaqing Zhao, Michael Warnick, Mauricio Villavicencio, Fabio Ius and 15 more

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15462 ↗

At a glance

Multizentrische Studie in Clinical Transplantation, 2024. Written by Mohammed Abul Kashem and 26 co-authors. Institution: Division of Cardiovascular Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: COVID-19, Lung Transplantation, SARS-CoV-2, Registries. Cited 1 times so far (Crossref); 24 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Lung transplantation has become increasingly utilized in patients with COVID‐19. While several single‐center and UNOS database studies have been published on lung transplants (LTs) for end‐stage lung disease (ESLD) from Coronavirus disease 2019 (COVID‐19), there is a lack of multi‐center and international data.

Methods

This is a multicenter analysis from 11 high‐volume lung transplant centers in the United States and Europe. Data were collected through the Multi‐Institutional ECLS Registry and stratified by ESLD due to COVID‐19 versus other etiologies. Demographics and clinical variables were compared using Chi‐square test and Fisher's exact test. Survival was assessed by Kaplan‐Meier curves and compared by log‐rank test with propensity score matching.

Results

Of 1606 lung transplant recipients, 46 (2.9%) were transplanted for ESLD from COVID‐19 compared to 1560 (97.1%) without a history of COVID‐19. Among COVID‐19 patients, 30 (65.2%) had COVID‐19‐associated ARDS and 16 (34.8%) had post‐COVID‐19 fibrosis. COVID‐19 patients had higher lung allocation scores (78.0 vs. 44.4, p < 0.0001), had severely limited functional status (37.0% vs. 2.9%, p < 0.0001), had higher preoperative ECMO usage (65.2% vs. 5.4%, p < 0.0001), and spent less time on the waitlist (32 vs. 137 days, p < 0.0001). A 30‐day survival was comparable between COVID‐19 and non‐COVID‐19 patients before (100% vs. 98.7%, p = 0.39) and after propensity matching ( p = 0.15).

Conclusions

Patients who received LTs due to COVID‐19 had short‐term survival comparable to that of patients without COVID‐19. Our findings support the idea that lung transplantation should be considered for select patients with ESLD due to COVID‐19.

Subjects

MeSH terms (MEDLINE)

COVID-19Lung TransplantationSARS-CoV-2RegistriesHumansMaleFemaleMiddle AgedUnited StatesSurvival RateAdultEuropeRetrospective StudiesAgedTreatment Outcome

Author keywords

fibrosislung (allograft) function/dysfunctionlung (native) function/dysfunctionpatient survival

Authors and institutions

  • Division of Cardiovascular Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.
  • Department of Cardiothoracic Transplant and Circulatory Support, Baylor College of Medicine, Houston, Texas, USA.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
  • Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA.

ORCID profiles: Gabriel Loor, Dirk Van Raemdonck, Hannah Calvelli, Marcelo Salan-Gomez, Jawad Salman, Pablo G Sanchez, Stephen Huddleston, Asishana Osho

Cite

APA

Kashem, M. A., Loor, G., Emtiazjoo, A., Hartwig, M., Van Raemdonck, D., Calvelli, H., Leon Pena, A., Salan-Gomez, M., Zhao, H., Warnick, M., Villavicencio, M., Ius, F., Ghadimi, K., Salman, J., Chandrashekaran, S., Machuca, T., Sanchez, P. G., Subramaniam, K., Neyrinck, A., …, & Toyoda, Y. (2024). A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19. Clinical Transplantation. https://doi.org/10.1111/ctr.15462

Vancouver

Kashem MA, Loor G, Emtiazjoo A, Hartwig M, Van Raemdonck D, Calvelli H, et al. A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19. Clinical Transplantation. 2024. doi:10.1111/ctr.15462

BibTeX
@article{Kashem2024,
  author = {Kashem, Mohammed Abul and Loor, Gabriel and Emtiazjoo, Amir and Hartwig, Matthew and Van Raemdonck, Dirk and Calvelli, Hannah and Leon Pena, Andres and Salan-Gomez, Marcelo and Zhao, Huaqing and Warnick, Michael and Villavicencio, Mauricio and Ius, Fabio and Ghadimi, Kamrouz and Salman, Jawad and Chandrashekaran, Satish and Machuca, Tiago and Sanchez, Pablo G and Subramaniam, Kathirvel and Neyrinck, Arne and Huddleston, Stephen and Ceulemans, Laurens and Osho, Asishana and D'Silva, Ethan and Ramamurthy, Uma and Shaffer, Andrew and Langer, Nathaniel and Toyoda, Yoshiya},
  title = {A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15462}
}
Start for free →